Caris Life Sciences opened lower at $23.66, compared with its previous close of $24.49. In the last trading session, the stock traded between $23.05 and $24.33. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Caris Life Sciences is now worth
$ 85.55
Resulting in a loss of
$ 14.45 (14.45%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
77.78%
Hold
22.22%
Sell
0%
Markets Today
Today's Change
$-0.54 (-2.18%)
Day High
$24.33
Day Low
$23.05
Day Open
$23.66
Prev Close
$24.49
Volume
30,04,056
1W Return
-27.93%
1M Return
-19.32%
3M Return
3.58%
6M Return
50.28%
1Y Return
-4.79%
Fundamentals
Market Cap ($ Mn)
6,870
PE Ratio
15.17
PB Ratio
12.25
PEG Ratio
-
ROE
-
ROCE
-4.52%
EPS (TTM)
-
Investment Returns
1 Week
-27.93%
1 Month
-19.32%
3 Months
3.58%
6 Months
50.28%
9 Months
11.42%
Financials
Quarterly
All values in $ Mn
181.4
Jun 25
216.8
Sep 25
292.9
Dec 25
216.2
Mar 26
263.7
Jun 26
275.4
Sep 26
Updates
10Nov
Piper Sandler raises Caris Life Sciences price target to $25
Piper Sandler maintains a Neutral rating on Caris Life Sciences. Price target increased from $22 to $25. Analyst David Westenberg authored the rating update.
2 days ago
7Nov
Citigroup maintains Buy on Caris Life Sciences, raises target to $36
Citigroup maintains a Buy rating on Caris Life Sciences. Price target increased from $28 to $36. Analyst Albert Hu issued the updated rating.
6 days ago
5Nov
Caris Life Sciences Q3FY26 Results: Revenue rises 27% to $275.4 million
Total revenue rose 27% YoY to $275.4 million, driven by 21% volume growth. Net income was $15.3 million, compared to $24.3 million in the prior year quarter. Adjusted EBITDA reached $44.4 million, marking the sixth consecutive positive quarter. Full-year revenue outlook raised to $1.04 billion-$1.05 billion. Cash and investments stood at $769.2 million at quarter end.
8 days ago
27Aug
Caris Life Sciences validates AI tool for pancreatic cancer treatment selection
Standard molecular risk patients predicted to benefit from FOLFIRINOX achieved 16.0 months median overall survival vs 9.9 months for gem/nab-p. Approximately half of patients in the study received therapy different from the AI model's recommendation. Caris AI Insights uses whole exome and transcriptome sequencing to guide treatment decisions for solid tumors. The tool is available at no additional cost with the FDA-approved MI Cancer Seek assay.
2mo ago
6Aug
Evercore ISI raises Caris Life Sciences price target to $26
Evercore ISI Group analyst Vijay Kumar maintains an Outperform rating on Caris Life Sciences (NASDAQ: CAI). The firm raised its price target from $25 to $26, indicating continued confidence in the company's growth prospects and strategic execution.
3mo ago
16Jul
Caris Life Sciences to report Q2 2026 results on August 5
Caris Life Sciences will announce its Q2 2026 financial results on August 5, 2026, followed by a live webcast at 3:30 p.m. CT. The company, a TechBio firm specializing in precision medicine, will provide a replay on its investor relations website.
